Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802

Multiple Sclerosis

Noseworthy, J. H., Lucchinetti, C. F., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 3,016

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

Lee, J. W., Devanarayan, V., Barrett, Y. C., WEINER, R. S., Allinson, J. L., Fountain, S. T., Keller, S., Weinryb, I., Green, M., Duan, L., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9045-3 · Cited by 771

Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss

Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688

Myelin and iron concentration in the human brain: a quantitative study of MRI contrast

Stüber, C., Morawski, M., Schäfer, A., Labadie, C., Wähnert, M., Leuze, C., Streicher, M., Barapatre, N., Reimann, K., Geyer, S., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.02.026 · Cited by 635

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Gaiottino, J., Norgren, N., Dobson, R., Topping, J. H., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 493

Concepts of myelin and myelination in neuroradiology.

Barkovich, A. J. (2000) · PubMed Central · Cited by 460

Neurochemical Aftermath of Amateur Boxing

Zetterberg, H., Hietala, M. A., Jonsson, M. A. G., Andreasen, N., Styrud, E., Karlsson, I., Edman, Å., Popa, C., Rasulzada, A., Wahlund, L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1277 · Cited by 366

How minimal variations in neuronal cytoskeletal integrity modulate cognitive control

Beste, C., Stock, A., Zink, N., Ocklenburg, S., Akgün, K., & Ziemssen, T. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.10.053 · Cited by 33

Neurofilament light is a treatment‐responsive biomarker in CLN2 disease

Ru, Y., Corado, C. R., Soon, R. K., Melton, A. C., Harris, A., Yu, G. K., Pryer, N., Sinclair, J. R., Katz, M. L., Ajayi, T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50942 · Cited by 30

Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients

Bridel, C., Verberk, I. M. W., Heijst, J. A., Killestein, J., & Teunissen, C. E. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102666 · Cited by 31

Vitamin D supplementation and neurofilament light chain in multiple sclerosis

Holmøy, T., Røsjø, E., Zetterberg, H., Blennow, K., Lindstrøm, J. C., Steffensen, L. H., & Kampman, M. T. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.13037 · Cited by 31

Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms

Kosa, P. F., Barbour, C. R., Varosanec, M., Wichman, A., Sandford, M., Greenwood, M., & Bielekova, B. (2022) · Nature Communications · doi:10.1038/s41467-022-35357-4 · Cited by 31

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies

Huss, A. M., Şenel, M., Abdelhak, A., Mayer, B., Kassubek, J., Ludolph, A. C., Otto, M., & Tumani, H. (2020) · Biomedicines · doi:10.3390/biomedicines8090312 · Cited by 29

“No evidence of disease activity”: Is it an aspirational therapeutic goal in multiple sclerosis?

Najjar, M. E., Eid, C., Khoury, S. J., & Hannoun, S. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.101935 · Cited by 29

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS

Engel, S., Steffen, F., Uphaus, T., Scholz-Kreisel, P., Zipp, F., Bittner, S., & Luessi, F. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000679 · Cited by 27

Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach

Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 29

Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants

Sjöbom, U., Hellström, W., Löfqvist, C., Nilsson, A., Holmström, G. E., Pupp, I. H., Ley, D., Blennow, K., Zetterberg, H., Sävman, K., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4138 · Cited by 26

Biosensors, Recent Advances in Determination of BDNF and NfL

Mobed, A., Charsouei, S., Yazdani, Y., Gargari, M. K., Ahmadalipour, A., Sadremousavi, S. R., Farrahizadeh, M., Shahbazi, A., & Haghani, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01401-0 · Cited by 27

Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial

de Flon, P., Laurell, K., Sundström, P., Blennow, K., Söderström, L., Zetterberg, H., Gunnarsson, M., & Svenningsson, A. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13078 · Cited by 24

Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring

Preziosa, P., Rocca, M. A., & Filippi, M. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1760846 · Cited by 27

Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS

Damasceno, A., Dias-Carneiro, R. P. C., Moraes, A. S., Boldrini, V. D. O., Quintiliano, R. P. S., da Silva, V. A. D. P. G., Farias, A. S., Brandão, C. O., Damasceno, B. P., dos Santos, L. M. B., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.02.004 · Cited by 24

The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years

Friedová, L., Motýl, J., Srpová, B., Oechtering, J., Barro, C., Vodehnalová, K., Andělová, M., Nosková, L., Fialová, L., Havrdová, E., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102534 · Cited by 24

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity

Masvekar, R., Phillips, J., Komori, M., Wu, T., & Bielekova, B. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.649876 · Cited by 23

Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease

Manniche, C., Simonsen, A. H., Hasselbalch, S. G., Andréasson, U., Zetterberg, H., Blennow, K., Høgh, P., Juhler, M., & Hejl, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200036 · Cited by 23

Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode

Plavina, T., Singh, C. M., Sangurdekar, D. P., de Moor, C., Engle, B., Gafson, A., Goyal, J., Fisher, E., Szak, S. T., Kinkel, R. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16278 · Cited by 23

Kynurenines and Neurofilament Light Chain in Multiple Sclerosis

Pukoli, D., Polyák, H., Rajda, C., & Vécsei, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.658202 · Cited by 24

CSF parameters associated with early MRI activity in patients with MS

Klein, A. P., Selter, R., Hapfelmeier, A., Berthele, A., Müller‐Myhsok, B., Pongratz, V., Gasperi, C., Zimmer, C., Mühlau, M., & Hemmer, B. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000573 · Cited by 23

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis

Tavazzi, E., Bergsland, N., Kühle, J., Jakimovski, D., Ramanathan, M. K., Maceski, A. M., Tomic, D., Hagemeier, J., Kropshofer, H., Leppert, D., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09643-z · Cited by 22

Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological–serological correlative study

Dietmann, A.-S., Kruse, N., Stork, L., Gloth, M., Brück, W., & Metz, I. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11468-2 · Cited by 23

Human Tridimensional Neuronal Cultures for Phenotypic Drug Screening in Inherited Peripheral Neuropathies

Maciel, R. D. M., Correa, R., Taniguchi, J. B., Araujo, I. P., & Saporta, M. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1718 · Cited by 22

Biochemical biomarkers for multiple sclerosis

Maroto‐García, J., Martínez‐Escribano, A., Gil, V. D., Mañez, M., Mugueta, C., Varo, N., la Torre, A. G.-D., & Ruiz‐Galdón, M. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117471 · Cited by 25

Science is 1% inspiration and 99% biomarkers

Dubuisson, N., Puentes, F., Giovannoni, G., & Gnanapavan, S. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517709362 · Cited by 22

Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis

Yik, J. T., Becquart, P., Gill, J., Petkau, J., Traboulsee, A. L., Carruthers, R. L., Kolind, S., Devonshire, V. A., Sayao, A., Schabas, A. J., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103366 · Cited by 21

Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis

LoPresti, P. (2022) · Biomedicines · doi:10.3390/biomedicines10051077 · Cited by 21

Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD)

Dardis, A., Pavan, E., Fabris, M., Riol, R. M. D., Sechi, A., Fiumara, A., Santoro, L., Ormazábal, M., Milanič, R., Zampieri, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204796 · Cited by 18

Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study

Lie, I. A., Kaçar, S., Wesnes, K., Brouwer, I., Kvistad, S. S., Wergeland, S., Holmøy, T., Midgard, R., Bru, A., Edland, A., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328568 · Cited by 18

Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors

Sapko, K., Jamróz-Wiśniewska, A., Marciniec, M., Kulczyński, M., Szczepańska-Szerej, A., & Rejdak, K. (2020) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2020.0037 · Cited by 19

Enhancing the clinical value of serum neurofilament light chain measurement

Kosa, P. F., Masvekar, R., Komori, M., Phillips, J., Ramesh, V., Varosanec, M., Sandford, M., & Bielekova, B. (2022) · JCI Insight · doi:10.1172/jci.insight.161415 · Cited by 19

Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients

Szilasiová, J., Rosenberger, J., Fedičová, M., Mikula, P., Urban, P., Gdovinová, Z., Vitková, M., Hanes, J., & Stevens, E. (2021) · European Neurology · doi:10.1159/000515806 · Cited by 17

Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort

Steffen, F., Uphaus, T., Ripfel, N., Fleischer, V., Schraad, M., González‐Escamilla, G., Engel, S., Groppa, S., Zipp, F., & Bittner, S. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200055 · Cited by 18

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study

Johnsson, M., Stenberg, Y., Farman, H. H., Blennow, K., Zetterberg, H., Malmeström, C., Sandgren, S., Rosenstein, I., Lycke, J., Axelsson, M., et al. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241237388 · Cited by 19

No evidence of disease activity (NEDA) in MS should include CSF biology — Towards a ‘Disease-Free Status Score’

Bonnan, M., Marasescu, R., Demasles, S., Krim, E., & Barroso, B. T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.12.001 · Cited by 17

Multiple sclerosis biomarkers: Helping the diagnosis?

Thouvenot, É. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.04.002 · Cited by 17

The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy

Pachner, A. R. (2022) · Biomedicines · doi:10.3390/biomedicines10092099 · Cited by 17

Multicenter Immunoassay Validation of Cerebrospinal Fluid Neurofilament Light: A Biomarker for Neurodegeneration

Miller, A.-M., Rutkowska, A., Bahl, J. M. C., Herukka, S., Simmelink, M. J. A., Kruse, N., Mollenhauer, B., Siloaho, M., Skinningsrud, A., Zetterberg, H., et al. (2016) · Bioanalysis · doi:10.4155/bio-2016-0114 · Cited by 16

Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen

Seo, G., Kim, S., Byun, J. C., Kwon, S., & Lee, Y. J. (2023) · Brain and Development · doi:10.1016/j.braindev.2023.07.005 · Cited by 18

Neurofilament in CSF—A biomarker of disease activity and long-term prognosis in multiple sclerosis

Sørensen, P. S., & Sellebjerg, F. T. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516658560 · Cited by 16

Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration

Birkner, K., Loos, J., Gollan, R., Steffen, F., Wasser, B., Ruck, T., Meuth, S. G., Zipp, F., & Bittner, S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00205 · Cited by 15

Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL

Gawde, S., Agasing, A. M., Bhatt, N., Toliver, M., Kumar, G., Massey, K., Nguyen, A., Mao‐Draayer, Y., Macwana, S., DeJager, W., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103922 · Cited by 16

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation

Baldassari, L. E., Planchon, S. M., Bermel, R. A., Nakamura, K., Fisher, E., Feng, J. J., Sakaie, K., Ontaneda, D., & Cohen, J. A. (2019) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217319887198 · Cited by 15

Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis

Singer, B. A., Morgan, D., Stamm, J. A., & Williams, A. A. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00654-1 · Cited by 14

Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis

Bader, J. M., Makarov, C., Richter, S., Strauss, M. T., Held, F., Wahle, M., Lorenz, M., Pöschl, L., Skowronek, P., Thielert, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.017 · Cited by 15

Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis

Miteva, D., Vasilev, G., & Velikova, T. V. (2023) · Antibodies · doi:10.3390/antib12040081 · Cited by 14

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping

Bielekova, B., & Pranzatelli, M. R. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.08.001 · Cited by 14

Liquordiagnostik bei Multipler Sklerose

Ruprecht, K., & Tumani, H. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0220-z · Cited by 14

Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis

Masvekar, R., Mizrahi, J., Park, J., Williamson, P., & Bielekova, B. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01241 · Cited by 15

MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis

Rosso, M., Healy, B. C., Saxena, S., Paul, A., Bjørnevik, K., Kühle, J., Benkert, P., Leppert, D., Guttmann, C. R. G., Bakshi, R., et al. (2021) · Journal of Neuroimaging · doi:10.1111/jon.12826 · Cited by 14

Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay

Ulndreaj, A., Sohaei, D., Thebault, S., Pons-Belda, O. D., Fernandez-Uriarte, A., Campbell, C. T., Cheo, D., Stengelin, M. K., Sigal, G. B., Freedman, M. S., et al. (2023) · Diagnosis · doi:10.1515/dx-2022-0125 · Cited by 13

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

Cutter, G., Rudick, R. A., de Moor, C., Singh, C. M., Fisher, E., Koster, T. M., LUBLIN, F. D., Wolinsky, J. S., McFarland, H. F., Jacobson, S., et al. (2023) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173231169463 · Cited by 13

Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss

Szilasiová, J., Mikula, P., Rosenberger, J., Fedičová, M., Gdovinová, Z., Urban, P., & Frigová, L. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458521998039 · Cited by 13

Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?

Khalil, M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518791518 · Cited by 13

Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis

Rosenkranz, S. C., Gutmann, L., Has, A. C., Dörr, M., Häußler, V., Lüpke, M., Mönch, A., Reinhardt, S., Kühle, J., Tilsley, P., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331183 · Cited by 11

Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis

Aburashed, R. A., Ghzawi, A., Long, D., Pace, R., Madha, A., & Cote, J. (2025) · Neurology International · doi:10.3390/neurolint17040056 · Cited by 13

Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis

Chertcoff, A. S., Schneider, R., Azevedo, C. J., Sicotte, N. L., & Oh, J. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.06.008 · Cited by 12

Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making

Valdeolivas, I. P., Zubizarreta, I., Martínez‐Lapiscina, E. H., & Villoslada, P. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1393315 · Cited by 11

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis

Bsteh, G., Berek, K., Hegen, H., Buchmann, A., Voortman, M. M., Auer, M., Wurth, S., Zinganell, A., Pauli, F. D., Deisenhammer, F., et al. (2019) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217319885987 · Cited by 11

CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis

Bhan, A., Jacobsen, C., Dalen, I., Bergsland, N., Zivadinov, R., Alves, G. W., Myhr, K., & Farbu, E. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211060337 · Cited by 11

Retinal Nerve Fiber Layer Thickness Correlates with Serum and Cerebrospinal Fluid Neurofilament and Nitrotyrosine Levels and is Associated with Current Disability in Multiple Sclerosis

Uzunköprü, C., Yüceyar, N., Yılmaz, S. G., Afrashı, F., Ekmekçi, Ö., & Taşkıran, D. (2020) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27355 · Cited by 10

Disease Biomarkers in Multiple Sclerosis: Current Serum Neurofilament Light Chain Perspectives

Jakimovski, D., Dwyer, M. G., Bergsland, N., Weinstock‐Guttman, B., & Zivadinov, R. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0058 · Cited by 10

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS

Lokhande, H., Rosso, M., Tauhid, S., Chu, R., Healy, B. C., Saxena, S., Barro, C., Paul, A., Polgar-Turcsanyi, M., Anderson, M., et al. (2022) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211069348 · Cited by 9

GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis

Martin, S., Brand‐Arzamendi, K., Saab, G., Muccilli, A. D., Oh, J., & Schneider, R. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231195861 · Cited by 9

Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis

Barrero, F. J., Villarrubia, A. R., Fernández, C. M., Martínez, V. G., del Moral, A. A., Barrios-López, J. M., Rivas, M. A. R., Muñoz, A. J. G., & Morales, R. P. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070692 · Cited by 9

Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study

Shim, Y. (2022) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2022.21.2.59 · Cited by 9

Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the REDUCE‐GAD trial

Schäefer, J. H., Schaller, M., Wenger, K. J., Mayer, C., Mann, U. M., Bickert, A., Steffen, F., Bittner, S., Yalachkov, Y., & Foerch, C. (2023) · European Journal of Neurology · doi:10.1111/ene.15865 · Cited by 9

Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis

Zhang, Y., Gu, J., Wang, X., Li, L., Fu, L.-L., Wang, D., Wang, X., & Han, X. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2042690 · Cited by 9

Multiple sclerosis treatment effects on plasma cytokine receptor levels

Bedri, S. K., Fink, K., Manouchehrinia, A., Lundström, W., Kockum, I. S., Olsson, T. P., Hillert, J. A., & Glaser, A. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.023 · Cited by 9

Advanced Brain Imaging in Central Nervous System Demyelinating Diseases

Cagol, A., Tsagkas, C., & Granziera, C. (2024) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.03.003 · Cited by 8

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Proschmann, U., Inojosa, H., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.650530 · Cited by 8

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?

Graetz, C., Groppa, S., Zipp, F., & Siller, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1438190 · Cited by 8

Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan

Hostenbach, S., Pauwels, A., Michiels, V., Raeymaekers, H., Vanbinst, A., Merhaegen-Wieleman, A. V., Schuerbeek, P. V., Keyser, J. D., & D’haeseleer, M. (2019) · Trials · doi:10.1186/s13063-019-3252-4 · Cited by 7

Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis

Hradílek, P., Revendová, K. Ž., Horakova, J., Bunganic, R., Pelíšek, O., Zeman, D., Hanzlíková, P., & Kušnierová, P. (2023) · Biomedical Papers · doi:10.5507/bp.2023.002 · Cited by 7

Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanismsPreprint

Barbour, C. R., Kosa, P. F., Varosanec, M., Greenwood, M., & Bielekova, B. (2020) · medRxiv · doi:10.1101/2020.05.18.20105932 · Cited by 7

ATXN7-Related Cone-Rod Dystrophy

Nassisi, M., Coarelli, G., Blanchard, B., Dubec‐Fleury, C., Drine, K., Kitic, N., Sancho, S., Hilab, R., du Montcel, S. T., Junge, C., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.0001 · Cited by 6

Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis

Saucier, L. E., Healy, B. C., Saxena, S., Sanon, E., & Chitnis, T. (2024) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173241274567 · Cited by 6

Pumping up the Fight against Multiple Sclerosis: The Effects of High-Intensity Resistance Training on Functional Capacity, Muscle Mass, and Axonal Damage

Maroto‐Izquierdo, S., Mulero, P., Menéndez, H., Pinto-Fraga, J., Lista, S., Santos‐Lozano, A., & Téllez, N. (2024) · Healthcare · doi:10.3390/healthcare12080837 · Cited by 6

‘Progressive MS – macro views’: The need for novel clinical trial paradigms to enable drug development for progressive MS

Zaratin, P., Comi, G., & Leppert, D. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517729457 · Cited by 6

Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis

Puz, P., Stęposz, A., Lasek‐Bal, A., Bartoszek, K., Radecka, P., & Karuga, A. (2017) · Neurological Research · doi:10.1080/01616412.2017.1403729 · Cited by 6

Comparative Analysis of Neurodegeneration and Axonal Dysfunction Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis

Kulczyńska‐Przybik, A., Dulewicz, M., Doroszkiewicz, J., Borawska, R., Litman‐Zawadzka, A., Arslan, D., Kułakowska, A., Kochanowicz, J., & Mroczko, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144122 · Cited by 6

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice

Beste, C., & Ziemssen, T. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00905 · Cited by 6

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

Foley, J. F., Xiong, K., Hoyt, T., Singh, C. M., Riddle, E. L., de Moor, C., Plavina, T., & Campbell, N. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221130949 · Cited by 5

Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer’s Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study

Shim, Y. (2023) · Current Alzheimer Research · doi:10.2174/0115672050284054240119101834 · Cited by 5

Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysis

Hermesdorf, M., Wulms, N., Maceski, A. M., Leppert, D., Benkert, P., Wiendl, H., Kühle, J., & Berger, K. (2023) · GeroScience · doi:10.1007/s11357-023-00846-x · Cited by 5

Serum NFL levels should be used to monitor multiple sclerosis evolution – No

Myhr, K., & Torkildsen, Ø. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519872891 · Cited by 5

Ibudilast

Sormani, M. P., Tur, C., & Barkhof, F. (2020) · Neurology · doi:10.1212/wnl.0000000000011312 · Cited by 5

Predicting upper limb disability progression in primary progressive multiple sclerosis using machine learning and statistical methods

Mostafa, S., Song, I. H. J., Metwally, A. A., Strauli, N. B., Sewde, N., Friesenhahn, M. J., Usdin, M., & Jia, X. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669665 · Cited by 4

Global research trends on the links between NfL and neurological disorders: A bibliometric analysis and review

Song, Z., Zhang, S., Pan, H., Hu, B., Liu, X., Cui, J., & Zhang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34720 · Cited by 4

Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis

Fedičová, M., Mikula, P., Gdovinová, Z., Vitková, M., Žilka, N., Hanes, J., Frigová, L., & Szilasiová, J. (2023) · Medicina · doi:10.3390/medicina59050865 · Cited by 4

Neurodegeneration and Multiple Sclerosis

Petzold, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_18 · Cited by 4

Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis

Alifirova, V. M., Kamenskikh, E. M., & Koroleva, E. S. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119107 · Cited by 5

Biomarkers of Disease Progression

Petzold, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-65921-3_6 · Cited by 4

Blood neurofilament light chain in patients with multiple sclerosis: A systematic review and updated meta-analysis

Ebrahimi, R., Seifi, M., Masouri, M. M., Nejad, M. R., Azad, G., Kabiri, A. H., & Noori, S. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112992 · Cited by 3

Neurofilaments in neurologic disease

Mousele, C., Holden, D., & Gnanapavan, S. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.010 · Cited by 3

Establishment of Neurofilament Light Chain in Plasma-Derived Neuronal Extracellular Vesicles as a Biomarker for Disease Progression in Multiple Sclerosis Patients

Praveena, G., Tummala, A., Kandadai, R. M., Yareeda, S., Nagaraju, V., Natarajan, V., Khilari, M. L., Balakrishna, N., Prakasham, R. S., Prabhakar, S., et al. (2024) · Neurochemical Journal · doi:10.1134/s1819712424700119 · Cited by 3

IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment

Sánchez‐Vera, I., Escudero, E., Muñoz, Ú., & Sádaba, M. C. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231189919 · Cited by 5

Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder

Li, Y., Liu, Y., Zhao, W., An, X., Zhang, F., Zhang, T., Liu, Y., Chen, D., Zeng, P., Yuan, M., et al. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578218 · Cited by 3

Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Arslan, B., Arslan, G. A., Tuncer, A., Karabudak, R., & Dinçel, A. S. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.7326 · Cited by 3

Comparison of orexin-A and neurofilament light chain levels in patients with relapsing-remitting multiple sclerosis: A pilot study

Saruhan, E., Korkmaz, M., Altıparmak, B., Tosun, K., & Kutlu, G. (2022) · Ideggyógyászati Szemle · doi:10.18071/isz.75.0223 · Cited by 2

Assessment of Serum Neurofilament Light Chain Protein in Multiple Sclerosis Patients

Wahed, M. A., Abdelghani, A., Lotfy, S., Hashish, A., & Gaban, E. (2023) · Zagazig University Medical Journal · doi:10.21608/zumj.2023.229678.2848

Correlations of serum neurofilament light chain and quantitative magnetic resonance imaging metrics in multiple sclerosis

Yik, J. T. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0396929

Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis

Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164

NfL Levels in CSF, Serum, and Plasma of RRMS and PPMS Patients in a Cross-sectional UCSF Cohort (P2.2-082)

Harp, C. T., Ma, X., Hendricks, R., Fischer, S. K., Eggers, E. L., von Büdingen, H. ‐., Towsend, M., & Herman, A. H. (2019) · Neurology · doi:10.1212/wnl.92.15_supplement.p2.2-082

Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)

Hamilton, M., Inserra, G., Ledoux, C., & Streicher, N. (2026) · Neurology · doi:10.1212/wnl.0000000000217595